Clinical-Stage Biotech

Pasithea Raises $60M to Advance MEK Program and R&D Pipeline

Miami, Florida, November 28, 2025 Pasithea Therapeutics has announced the pricing of a $60 million public offering ,strengthening its...

By cGxPwire Editor
December 1, 2025

Bio-Pharma

Wave Life Sciences Advances RNA Innovation Ahead of Q3 2025 Results

CAMBRIDGE, Mass., November 4, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company pioneering the use...

By cGxPwire Editor
November 5, 2025

Bio-Pharma

Verismo Partners with Miltenyi Biotec to Advance KIR-CAR Clinical Programs

Philadelphia, September 25, 2025 – Verismo Therapeutics, a clinical-stage biotechnology company specializing in KIR-CAR T cell therapies, has announced...

By cGxPwire Editor
September 25, 2025

Bio-Pharma

Monte Rosa and Novartis Expand Degrader Alliance in Immunology

BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...

By cGxPwire Editor
September 15, 2025

.Clinical Bio-Pharma

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...

By cGxPwire Editor
September 4, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Pasithea Raises $60M to Advance MEK Program and R&D Pipeline

Wave Life Sciences Advances RNA Innovation Ahead of Q3 2025 Results

Verismo Partners with Miltenyi Biotec to Advance KIR-CAR Clinical Programs

Monte Rosa and Novartis Expand Degrader Alliance in Immunology

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price